Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; hydrochloric acid; benzoic acid; purified water - risperidone bnm is indicated for the treatment of schizophrenia and related psychoses.,risperidone bnm is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,risperidone bnm is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,risperidone bnm is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,risperidone bnm is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; benzoic acid; purified water; hydrochloric acid - rixadone is indicated for the treatment of schizophrenia and related psychoses.,rixadone is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,rixadone is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,rixadone is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,rixadone is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - neostigmine methylsulfate, quantity: 2.5 mg; glycopyrronium bromide, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; citric acid; dibasic sodium phosphate dodecahydrate; sodium hydroxide - reversal of residual non-depolarising (competitive) neuromuscular block.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - 44034 - blood donor set, double-pack - jms double blood bags are designed for the collection, preservation and transfusion of whole blood. through the process of centrifugation and extraction, the collected whole blood can be separated into red blood cells, plasma, buffy coat and platelets.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - 44037 - blood donor set, triple-pack - jms blood bags are designed for the collection, preservation and transfusion of whole blood. through the processes of centrifugation and extraction, the collected whole blood can be separated into red blood cells, plasma, buffy coat and platelets.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - 38522 - pipette, single channel/multichannel, mechanical - a measuring pipette to administer oral medications (such as oral solutions).